Abstract: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing cellular energy production thereby providing energy for the continuous activation of PARP-1 and up-regulation of PPAR. It is well known that chronic activation of PARP causes ATP and NAD depletion with concomitant cell death. PARP is known to prevent HIV replication by competitive receptor inhibition. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms “methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid” are used interchangeably.

Abstract: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular energy production. Methyl pyruvate compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination disorders, or cellular disorders which interfere with the energy metabolism of neurons and mitochondrial diseases. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis.

Abstract: The present invention relates to a composition comprising a mixture of nutritional co-factors synergistically combined and applied as a transdermal surfactant. Said surfactant has the ability to introduce locally, required nutrients that modulate chronic or acute inflammation, thereby promoting the systemic repair of joint and soft tissue damage, with concomitant relief of pain. Each of the ingredients serves as a co-synergist in a series of intertwined biochemical loops to substantiate each individual ingredient and to form a positive synergistic response operating in concert. This provides the insitu systems of the body nutrients required to repair injured, damaged or diseased joints, and soft tissue as a result of oxidative insult, stress, injury or disease.

Abstract: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of reducing weight (fat) gain in mammals by orally administering therapeutically effective amounts of methyl pyruvate. The method also has the effect of increasing body protein concentration, improving insulin resistance, lower fasting insulin levels, preventing fat deposition and increasing cellular energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt.

Abstract: The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing muscle energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt. The methyl pyruvate compounds which can be used in the present method include: (1) a salt using a monovalent cation (such as sodium or potassium methyl pyruvate) or (2) a divalent cation (such as calcium or magnesium methyl pyruvate) and analogs of these compounds which can act as substrates or substrate analogs for methyl pyruvate Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms “methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid” are used interchangeably.